# US 2021/0196836 A1 · Formulation of nanostructured gels for increased agent loading and adhesion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196836 A1
- Document ID: US20210196836A1
- Status: Published application
- Kind: A1
- Application number: 17/137,931
- Filed: 2020-12-30
- Published: 2021-07-01
- Earliest claimed: 2017-05-08
- Assignees: Alivio Therapeutics, Inc.
- Applicants: Alivio Therapeutics, Inc.
- Inventors: Derek G. van der Poll; Dominick J. Blasioli; Gregory T. Zugates
- Web page: https://patentgrep.com/patent/US20210196836A1

## CPC

- A61K 47/6903: {the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A gel formulation has been developed which provides high loading, e.g., between about 5% and about 50% wt/wt agent/total gel weight, of a wide range of agents, especially amine-containing compounds such as local anesthetic agents that are known to be difficult to encapsulate, and which adhere to charged surfaces. Examples of pharmaceutically important amines include anesthetics, such as lidocaine. Tuning the ionic strength of an aqueous medium during preparation, suspension, and dialysis purification of the hydrogel composition allows for retention and/or control of agent loading contents, as well as a high capacity for adhesion to charged surfaces mimicking inflamed tissue. In some instances, the rheological properties of the gel can be tuned such as to impart thixotropic properties to the gels formed.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A gel composition comprising nanostructures and formed from a homogenous solution comprising
a gelator having a molecular weight of 2,500 Da or less,
one or more local anesthetic agents comprising an ionizable tertiary amine functional group which can exist as an uncharged free base or in a cationic form, and
a gelation medium comprising water and one or more water-miscible organic solvents comprising dimethylsulfoxide, acetone, dimethylformamide, tetrahydrofuran, dioxane, acetonitrile, or alcohols with a water solubility greater than 5 g/100 g of water,
wherein the gelation medium comprises between 10 mM and 500 mM of one or more salts when the one or more water-miscible organic solvents comprise dimethylsulfoxide, acetone, dimethylformamide, tetrahydrofuran, dioxane, or acetonitrile,
wherein the formed gel composition is stable to inversion at room temperature, and
wherein the one or more local anesthetic agents are encapsulated, entrapped, and/or embedded in the nanostructures of the gel composition via electrostatic interactions between the local anesthetic agents and the gelator of the gel composition, at between about 5% and about 25% by weight in the nanostructures of the gel composition.

### Claim 27 (depends on 26)

The gel composition of claim 26, wherein the one or more salts, when present, mediate and/or modify the electrostatic interactions between the local anesthetic agents and the gelator.

### Claim 28 (depends on 26)

The gel composition of claim 26, wherein the one or more salts, when present, are selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, zinc chloride, monosodium phosphate, and combinations thereof.

### Claim 29 (depends on 26)

The gel composition of claim 26, wherein the one or more salts, when present, are present in the gel composition at a concentration between about 15 to about 150 mM.

### Claim 30 (depends on 26)

The gel composition of claim 26, wherein the gel composition is dried or lyophilized to remove all solvents.

### Claim 31 (depends on 30)

The gel composition of claim 30, wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropanol, t-butanol, and combinations thereof.

### Claim 32 (depends on 30)

The gel composition of claim 30, wherein the one or more water-miscible organic solvents are present in the gel composition at a concentration between about 0.1 and 25% volume/volume of total gel.

### Claim 33 (depends on 26)

The gel composition of claim 26, wherein the gel has a viscosity between about 0.1 and about 1,000 cP.

### Claim 34 (depends on 26)

The gel composition of claim 26, wherein the gel composition formed is a thixotropic gel composition.

### Claim 35 (depends on 34)

The gel composition of claim 34, wherein the gel has a G′ or G″ value of from about 0.1 to about 300 Pa.

### Claim 36 (depends on 26)

The gel composition of claim 26, wherein the gel has a shear-dependent viscosity.

### Claim 37 (depends on 26)

The gel composition of claim 26, wherein the gelation medium comprises distilled water, de-ionized water, pure or ultrapure water, saline, or other physiologically acceptable aqueous solutions.

### Claim 38 (depends on 26)

The gel composition of claim 26, wherein the one or more local anesthetic agents are selected from the group consisting of lidocaine, procaine, tetracaine, dibucaine, bupivacaine, and salts thereof.

### Claim 39 (depends on 26)

The gel composition of claim 26, wherein the gelator is selected from:
an ascorbyl alkanoate selected from the group consisting of ascorbyl palmitate, ascorbyl decanoate ascorbyl laurate, ascorbyl caprylate, ascorbyl myristate, ascorbyl oleate, and combinations thereof;
a sorbitan alkanoate selected from the group consisting of sorbitan monostearate, sorbitan decanoate, sorbitan laurate, sorbitan caprylate, sorbitan myristate, sorbitan oleate, and combinations thereof;
a triglycerol monoalkanoate selected from the group consisting of triglycerol monopalmitate, triglycerol monodecanoate, triglycerol monolaurate, triglycerol monocaprylate, triglycerol monomyristate, triglycerol monostearate, triglycerol monooleate, and combinations thereof;
a sucrose alkanoate selected from the group consisting of sucrose palmitate, sucrose decanoate, sucrose laurate, sucrose caprylate, sucrose myristate, sucrose oleate, and combinations thereof;
and combinations thereof.

### Claim 40 (depends on 26)

The gel composition of claim 26, wherein the gel composition is formed after heating the homogeneous solution and cooling the homogeneous solution to room temperature.

### Claim 41 (depends on 26)

The gel composition of claim 26, wherein the gel composition formed is stable to inversion for at least 60 minutes at room temperature.

### Claim 42 (depends on 26)

The gel composition of claim 26, wherein the one or more salts, when present, are selected from the group consisting of monosodium phosphate, disodium phosphate, and monopotassium phosphate.

### Claim 43 (depends on 26)

The gel composition of claim 26, wherein the gelation medium comprises a phosphate buffered saline at physiological ionic strength.

### Claim 44 (depends on 26)

The gel composition of claim 26, comprising at least 4% wt gelator/vol.

### Claim 45 (depends on 26)

The gel composition of claim 26, wherein the one or more salts, when present, are present in the gel composition at a concentration between about 20 mM to about 150 mM salt.

### Claim 46 (depends on 26)

The gel composition of claim 26, wherein the gel has a viscosity between about 1 and about 400 cP.

### Claim 47 (depends on 26)

The gel composition of claim 26, wherein the gel has a viscosity between about 1 and about 10 cP.

### Claim 48 (depends on 26)

A pharmaceutical formulation comprising the gel composition of claim 26 in a pharmaceutically acceptable carrier,
optionally wherein the gel composition is in the form of gel particles.

### Claim 49 (depends on 26)

A method of forming the self-assembled gel composition of claim 26, comprising:
preparing a homogenous solution comprising
a gelator having a molecular weight of 2,500 Da or less and one or more local anesthetic agents comprising an ionizable tertiary amine functional group which can exist as an uncharged free base or in a cationic form in a gelation medium comprising water and one or more water-miscible organic solvents comprising dimethylsulfoxide, acetone, dimethylformamide, tetrahydrofuran, dioxane, acetonitrile, or alcohols with a water solubility greater than 5 g/100 g of water, and between 10 mM and 500 mM of one or more salts when the one or more water-miscible organic solvents comprise dimethylsulfoxide, acetone, dimethylformamide, tetrahydrofuran, dioxane, or acetonitrile;
permitting the homogenous solution to self-assemble into a self-assembled gel composition;
wherein the one or more local anesthetic agents are encapsulated, entrapped, and/or embedded in the nanostructures of the self-assembled gel composition via electrostatic interactions between the local anesthetic agents and the gelator of the self-assembled gel composition, at between about 5% and about 25% by weight in the nanostructures of the self-assembled gel composition.

### Claim 50 (depends on 49)

The method of claim 49, wherein the one or more salts, when present, are selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, zinc chloride, monosodium phosphate, and combinations thereof.

### Claim 51 (depends on 49)

The method of claim 49, wherein the one or more local anesthetic agents are selected from the group consisting of lidocaine, procaine, tetracaine, dibucaine, bupivacaine, and salts thereof.

### Claim 52 (depends on 49)

The method of claim 49, wherein the gelator is selected from:
an ascorbyl alkanoate selected from the group consisting of ascorbyl palmitate, ascorbyl decanoate ascorbyl laurate, ascorbyl caprylate, ascorbyl myristate, ascorbyl oleate, and combinations thereof;
a sorbitan alkanoate selected from the group consisting of sorbitan monostearate, sorbitan decanoate, sorbitan laurate, sorbitan caprylate, sorbitan myristate, sorbitan oleate, and combinations thereof;
a triglycerol monoalkanoate selected from the group consisting of triglycerol monopalmitate, triglycerol monodecanoate, triglycerol monolaurate, triglycerol monocaprylate, triglycerol monomyristate, triglycerol monostearate, triglycerol monooleate, and combinations thereof;
a sucrose alkanoate selected from the group consisting of sucrose palmitate, sucrose decanoate, sucrose laurate, sucrose caprylate, sucrose myristate, sucrose oleate, and combinations thereof;
and combinations thereof.

### Claim 53 (depends on 49)

The method of claim 49, wherein the one or more salts, when present, are selected from the group consisting of monosodium phosphate, disodium phosphate, and monopotassium phosphate.

### Claim 54 (depends on 49)

The method of claim 49, wherein the gelation medium comprises a phosphate buffered saline at physiological ionic strength.
